ATG4B and chronic myelogenous leukemia, BCR-ABL1 positive: Importantly, depletion of ATG4B also sensitized CML cancer stem cells to imatinib treatment, which indicates that inhibiting autophagy in combination with imatinib would have therapeutic potential in the treatment of CML (Rothe et al., 2014).